Skip to main content
Contact Us
Subscribe
E-Edition
95°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mainz Biomed N.V. - Ordinary Shares
(NQ:
MYNZ
)
0.6250
-0.0350 (-5.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mainz Biomed N.V. - Ordinary Shares
< Previous
1
2
3
4
Next >
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
June 03, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Reports Results of 2024 Annual General Meeting
May 31, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
May 28, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
May 20, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
May 07, 2024
The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82%
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
April 25, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Reports Full Year 2023 Financial Results
April 09, 2024
ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 Million
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
March 19, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
March 18, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
March 12, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
March 05, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
February 27, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
February 22, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
February 21, 2024
Partnership Brings Pioneering Approach to Incorporating Advanced Colorectal Cancer Detection Into Country’s Healthcare System
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
February 06, 2024
Company opens own physician-led laboratory, ‘European Oncology Lab’ (EOL), thereby offering ColoAlert® as a laboratory medical service directly to physicians and patients
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
January 11, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Provides Year-End Corporate Review 2023
January 09, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
December 19, 2023
Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and...
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
December 12, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
December 05, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
November 29, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 16, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
November 15, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
November 13, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
November 09, 2023
Collaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
November 07, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
October 31, 2023
Almost half of Zöller-KipperGmbH’s employees in Germany participated in the screening program so far using ColoAlert®, Mainz Biomed’s user-friendly, at-home colorectal cancer (CRC) screening test
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
October 26, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
October 18, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.